

## Special Issue

# Radiopharmaceuticals for Cancers

### Message from the Guest Editors

We are seeing an unprecedented number of radiopharmaceuticals entering clinical settings for the diagnosis and treatment of cancers. Several PET imaging agents targeting the estrogen receptor and prostate-specific membrane antigen have been approved for clinical use in the past two years, and clinical investigation is underway for other promising targets such as the fibroblast-activating protein. From a therapeutic perspective, there is rapid growth and adoption of beta emitters for treatment of neuroendocrine tumor and prostate cancer, and multiple novel radiopharmaceuticals including alpha emitters are on the horizon. Given the significant interest, from both academia and industry, we anticipate this accelerating trend for radiopharmaceutical development to continue. This special issue will highlight recent developments in diagnostic and therapeutic radiopharmaceuticals for cancers from bench to bedside.

---

### Guest Editors

Dr. Joseph Lau

Department of Integrative Oncology, British Columbia Cancer Agency, Vancouver, BC V5Z 1L3, Canada

Dr. Hwan Lee

Department of Radiology, Massachusetts General Hospital, Boston, MA 02114, USA

---

### Deadline for manuscript submissions

closed (30 October 2025)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/178586](https://mdpi.com/si/178586)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)